FDA Panel Unanimously Backs Cannabis Drug for Severe Epilepsy FDA Panel Unanimously Backs Cannabis Drug for Severe Epilepsy
An FDA advisory committee has voted to support approval of a formulation of cannabidiol as an adjunctive treatment for Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years of age or older.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news